The first confirmed Ebola case in the U.S. is fanning fears around the country, but it's also driving greed in some corners of the stock market.
Just look at the soaring stock price of drug companies scrambling to come up with a cure for the disease, which has killed more than 3,000 people in West Africa.
Tekmira Pharmaceuticals (TKMR) surged over 18% on Wednesday, leaving it up a whopping 180% since mid-July. Investors are betting the Vancouver-based company has a leg up on competitors because last month the FDA gave it a green light to provide its experimental TKM-Ebola drug to test subjects with "confirmed or suspected Ebola virus infections."
Richard Sacra, the American missionary infected with Ebola in Liberia, was given the drug last month before being released from a hospital in Nebraska.
(CNN)
